News Feature |
Featured
-
-
News |
Reprogrammed cells trigger immune reactions in mice
Medical applications of induced pluripotent stem cells called into question.
- Erika Check Hayden
-
-
News |
California ponders cell-banking venture
State agency grapples with technical and ethical challenges.
- Erika Check Hayden
-
Research Highlights |
New ways to change fates
-
Letter |
Modelling schizophrenia using human induced pluripotent stem cells
- Kristen J. Brennand
- , Anthony Simone
- & Fred H. Gage
-
News & Views |
The dark side of induced pluripotency
Induced pluripotent stem cells have great therapeutic potential. But genomic and epigenomic analyses of these cells generated using current technology reveal abnormalities that may affect their safe use. See Articles p.58, p.63 & p.68
- Martin F. Pera
-
Article |
Copy number variation and selection during reprogramming to pluripotency
Reprogramming of somatic cells to induced pluripotent stem (iPS) cells that can be differentiated into many cell types has great potential for personalized therapy. By comparing copy number variations of early- and intermediate-passage human iPS cells to their respective parental fibroblast cells and human embryonic stem (ES) cells, this study finds that a high mutation rate is associated with the reprogramming process. However, during moderate length culture, human iPS cells undergo a selection process leading to decreased mutation load of cells equivalent to that observed in human ES cells.
- Samer M. Hussein
- , Nizar N. Batada
- & Timo Otonkoski
-
Letter |
Recapitulation of premature ageing with iPSCs from Hutchinson–Gilford progeria syndrome
- Guang-Hui Liu
- , Basam Z. Barkho
- & Juan Carlos Izpisua Belmonte
-
News |
Flaw in induced-stem-cell model
Adult cells do not fully convert to embryonic-like state.
- Elie Dolgin
-
-
Research Highlights |
Stem cells: Platelets get a boost
-
Research Highlights |
Stem cells: Reprogramming cells with RNA
-
Research Highlights |
Stem cells: Blood source
-
Letter |
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
The generation of induced pluripotent stem cells (iPSCs) from patients with defined genetic disorders promises to help the basic understanding of complex diseases and the development of therapeutics. Here iPSCs have been generated from patients with LEOPARD syndrome, a developmental disorder with pleiomorphic effects on several tissues and organs. The iPSCs are characterized and the phenotype of cardiomyocytes derived from these cells is investigated.
- Xonia Carvajal-Vergara
- , Ana Sevilla
- & Ihor R. Lemischka
-
Highlights |
Opportunities: The National Institutes of Health
-
Highlights |
Opportunities: The National Institutes of Health
-
Highlights |
Opportunities: The National Institutes of Health
-
Article |
Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells
Induced pluripotent stem cells (iPSCs) are generated by the enforced expression of particular transcription factors in somatic cells. The extent to which such cells are equivalent to embryonic stem (ES) cells is an open question. Here, genetically identical mouse ES cells and iPSCs have been compared; the overall expression patterns of messenger RNAs and microRNAs are the same, with the exception of a few transcripts encoded within an imprinted gene cluster on chromosome 12qF1.
- Matthias Stadtfeld
- , Effie Apostolou
- & Konrad Hochedlinger
-
Highlights |
Opportunities: The National Institutes of Health
-
News |
Gene flaw found in induced stem cells
Key difference between reprogrammed adult mouse cells and embryonic stem cells discovered.
- Elie Dolgin
-
Letter |
Tbx3 improves the germ-line competency of induced pluripotent stem cells
The transcription factor Tbx3 is shown to significantly improve the quality of induced pluripotent stem (iPS) cells. Tbx3 binding sites in embryonic stem cells are present in genes involved in pluripotency and reprogramming factors. Furthermore, there are intrinsic qualitative differences in iPS cells generated by different methods in terms of their pluripotency, thus highlighting the need to rigorously characterize iPS cells beyond in vitro studies.
- Jianyong Han
- , Ping Yuan
- & Bing Lim
-
News |
Britain grants patent for iPS cells
The first issued outside Japan for reprogrammable stem cells credits different inventors.
- Sabin Russell